logo
  

Interactive Brokers Posts Loss In Q1 - Quick Facts

Interactive Brokers Group, Inc. (IBKR) reported a first-quarter net loss to shareholders of $13 million or $0.22 per share, compared to profit of $19 million or $0.34 per share, prior year. Comprehensive loss per share was $0.24, for the quarter.

On average, four analysts polled by Thomson Reuters expected the company to report a loss per share of $0.07 for the quarter. Analysts' estimates typically exclude special items.

The company noted that the results for the first quarter of 2015 were negatively impacted by a $121 million net loss due to the sudden move in the value of the Swiss franc, causing several of the company's customers who held currency futures and spot positions to suffer losses in excess of their deposits; and a $197 million loss on currency diversification strategy due to the strengthening of the U.S. dollar against other major currencies.

Revenue decreased to $172 million from $355 million last year. Analysts expected revenue of $194.83 million for the quarter.

The Interactive Board declared a quarterly cash dividend of $0.10 per share. The dividend is payable on June 12, 2015 to shareholders of record as of June 1, 2015.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT